
Ingredient in common kitchen herbs could target Alzheimer's, but don't change any recipes just yet
Experts believe they've identified a chemical compound in certain herbs that could help mitigate or prevent Alzheimer's disease — but before anyone makes a run for the spice rack, there are a few catches.
In a study published in the journal Antioxidants earlier this year, researchers from the Scripps Research Institute identified a compound called carnosic acid, which is prevalent in rosemary and sage.
The compound could prove therapeutic for neurodegenerative disorders, including Alzheimer's disease, the experts concluded.
Carnosic acid contains "striking antioxidant [and] anti-inflammatory properties," the researchers wrote in the findings.
Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, based in California, spoke with Fox News Digital about the results.
"In this study, we observed that administering this drug to mice that had advanced Alzheimer's-like disease significantly improved the number of neurons, as well as the number of synapses or connections between the brain cells," the team said.
The experts added, "It also reduced inflammation that is caused by the current anti-amyloid antibody therapies. We also observed an improvement in the learning and memory behavior of the mice that received the drug."
"From the results of our animal studies, we are cautiously optimistic for its success in the human clinical trials."
Banerjee and Lipton also noted that carnosic acid is a "prodrug," meaning it's inactive at first — but once it enters the body, it's activated by oxidative and inflammatory stress.
"It specifically targets cells undergoing oxidative and inflammatory stress, without affecting the healthy, normal brain cells," Banerjee said.
"This further makes it a safe option for therapeutics."
The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains.
There are cautions, however.
Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, told Fox News Digital that studies based on a mouse model of Alzheimer's can be helpful but are not conclusive.
There is insufficient clinical evidence to recommend rosemary and sage as a standard therapy.
"Models are important in helping us understand the basic biology of the disease, but we need human studies in representative populations for ideas to be fully validated," Kloske said.
"Therefore, while these are intriguing findings, more research is needed to understand the impacts and outcomes of these compounds on people living with, or at risk for, Alzheimer's."
Cooking sage and rosemary won't provide the full anti-inflammatory effects, Banerjee and Lipton stressed.
"Critically, one cannot take sufficient herbs safely to produce the same effect as our new drug," Banerjee said.
The study, funded in part by the National Institutes of Health, did have some limitations, the researchers acknowledged.
Kloske advised that, at this point, "no one should consume these herbs (or carnosic acid) to prevent or treat Alzheimer's or other cognitive impairment."
Dr. Lee Murray, a neurologist in Jackson, Tennessee, echoed Kloske's concerns.
"Before patients start incorporating rosemary and sage in every dish they eat, we need to remember these studies are pre-clinical," Murray told Fox News Digital.
"Currently, there is insufficient clinical evidence to recommend rosemary and sage as a standard therapy for Alzheimer's dementia."
Murray, however, said the data "is encouraging" and opens the door to additional pathways for potential therapeutics.
Banerjee said she hopes that "our drug will start human clinical trials soon."
She added, "If it proves to be effective, it will be a great new drug for those suffering from Alzheimer's … From the results of our animal studies, we are cautiously optimistic for its success in human clinical trials."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its 'Buy' rating on Iovance's stock on June 3. The firm also maintained its $34.00 price target for Iovance shares. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy's safety profile, which, according to Goldman Sachs, reinforces Amtagvi's potential as a significant treatment option. Goldman Sachs's analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi's responses. The firm emphasized Amtagvi's successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug's first full calendar year of sales in 2025 as a key driver. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient's own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance's pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 26, William Blair reaffirmed its 'Market Perform' rating for Maravai stock. The key factor influencing this move is the leadership changes at Maravai. A scientist performing a blood test on a patient using life sciences tools & services. Maravai has undergone a complete leadership overhaul since December last year. In December 2024, the company brought in Andy Eckert as the new independent Chairman of the Board. Later, Maravai installed Bernd Brust as CEO, replacing Trey Martin. Then, on June 25, a new press release indicated that Rajesh 'Raj' Asarpota would assume the position of Executive Vice President and Chief Financial Officer, effective June 30. According to William Blair, Brust and Asarpota are joining Maravai's top-level management when the company is undergoing 'a challenging operational transition period.' The analysts noted that the company 'faces approximately $66 million in headwinds in 2025 from declining COVID-related revenues.' As such, the analysts are optimistic that the fresh hands at Maravai's helm will inject more momentum into the transition. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company. It provides specialized products that support the development of vaccines, drug therapies, diagnostics, and cell and gene therapies. Its operations span two segments: Nucleic Acid Production and Biologics Safety Testing. While we acknowledge the potential of MRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data